728 related articles for article (PubMed ID: 28258828)
21. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
22. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
23. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
24. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
25. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
[TBL] [Abstract][Full Text] [Related]
26. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
27. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.
Lilleyman JS; Lennard L
Lancet; 1994 May; 343(8907):1188-90. PubMed ID: 7909868
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
29. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
Larsen RH; Utke Rank C; Grell K; Nørgaard Møller L; Malthe Overgaard U; Kampmann P; Nersting J; Degn M; Nygaard Nielsen S; Holst H; Klug Albertsen B; Skov Wehner P; Thude Callesen M; Kanerva J; Leth Frandsen T; Als-Nielsen B; Lyngsie Hjalgrim L; Schmiegelow K
Haematologica; 2021 Nov; 106(11):2824-2833. PubMed ID: 34047177
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
[TBL] [Abstract][Full Text] [Related]
31. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
[TBL] [Abstract][Full Text] [Related]
32. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
Schmiegelow K; Heyman M; Gustafsson G; Lausen B; Wesenberg F; Kristinsson J; Vettenranta K; Schroeder H; Forestier E; Rosthoej S;
Leukemia; 2010 Apr; 24(4):715-20. PubMed ID: 20130603
[TBL] [Abstract][Full Text] [Related]
33. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
Nersting J; Nielsen SN; Grell K; Paerregaard M; Abrahamsson J; Lund B; Jonsson OG; Pruunsild K; Vaitkeviciene G; Kanerva J; Schmiegelow K;
Cancer Chemother Pharmacol; 2019 Jan; 83(1):53-60. PubMed ID: 30324220
[TBL] [Abstract][Full Text] [Related]
35. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
[TBL] [Abstract][Full Text] [Related]
36. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
Lancaster DL; Patel N; Lennard L; Lilleyman JS
Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
[TBL] [Abstract][Full Text] [Related]
37. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
Veerman AJ; Hählen K; Kamps WA; Van Leeuwen EF; De Vaan GA; Solbu G; Suciu S; Van Wering ER; Van der Does-Van der Berg A
J Clin Oncol; 1996 Mar; 14(3):911-8. PubMed ID: 8622039
[TBL] [Abstract][Full Text] [Related]
38. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
Toksvang LN; Grell K; Nersting J; Degn M; Nielsen SN; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Lepik K; Vaitkevičienė G; Griškevičius L; Quist-Paulsen P; Vora A; Moorman AV; Murdy D; Zimmermann M; Möricke A; Bostrom B; Joshi J; Hjalgrim LL; Dalhoff KP; Als-Nielsen B; Schmiegelow K
Leukemia; 2022 Jan; 36(1):33-41. PubMed ID: 34175901
[TBL] [Abstract][Full Text] [Related]
39. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M
N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954
[TBL] [Abstract][Full Text] [Related]
40. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]